Canaccord Genuity maintains MapLight Therapeutics at Buy, keeps price target at $21

Canaccord Genuity reaffirmed its Buy rating and $21 price target for MapLight Therapeutics, implying a 204.3% upside from the Nov 16 close of $6.90.

Original reporting
Published Nov 17, 2026, 3:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 3:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canaccord Genuity maintains MapLight Therapeutics at Buy, keeps price target at $21 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Because the article contains no new company event, the main trading relevance is sentiment support from the reiterated rating and target.

02

Market read

This is primarily a sentiment/positioning input rather than a fresh fundamental driver.

03

What to watch

Traders may focus more on upcoming company-specific catalysts (trial readouts, regulatory milestones) than on a maintained analyst target.

Relevance 4/10Novelty 3/10Timing: as soon as the analyst note is picked up by the market

Background

The piece is an analyst-maintenance update from Canaccord Genuity, reiterating a Buy rating and a $21 price target for MapLight Therapeutics.

Market effects

Minimal sector impact; this is a single-name analyst reiteration without new biotech catalyst details.

No clear regional spillover indicated.

Limited global relevance; no cross-market macro or major industry event is described.

Counterpoint

The unchanged target and reiterated Buy may already be priced in, so the note may not move the stock meaningfully.

Key entities

  • MapLight Therapeutics

    Subject of the analyst note, rated Buy with a maintained $21 price target.

  • Canaccord Genuity

    Brokerage issuing the maintained Buy rating and unchanged price target.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in